Search results for "RESPIRATORY"

showing 10 items of 5091 documents

Nrf2 expression driven by Foxp3 specific deletion of Keap1 results in loss of immune tolerance in mice

2020

European journal of immunology 50(4), 515-524 (2020). doi:10.1002/eji.201948285

0301 basic medicineNF-E2-Related Factor 2T cellImmunologyAutoimmunitychemical and pharmacologic phenomenaBiologyLymphocyte ActivationT-Lymphocytes Regulatorydigestive systemenvironment and public healthImmune toleranceImmunomodulationMice03 medical and health sciences0302 clinical medicineImmune systemImmune TolerancemedicineAnimalsHomeostasisImmunology and AllergyTranscription factorPI3K/AKT/mTOR pathwayInflammationMice KnockoutKelch-Like ECH-Associated Protein 1ChimeraEffectorTOR Serine-Threonine KinasesPeripheral toleranceFOXP3Forkhead Transcription Factorshemic and immune systemsrespiratory systemCell biologyMice Inbred C57BLOxidative Stress030104 developmental biologymedicine.anatomical_structure030215 immunology
researchProduct

Role of oxidative stress in neonatal respiratory distress syndrome

2019

Respiratory distress syndrome is the commonest respiratory disorder in preterm infants. Although it is well known that preterm birth has a key role, the mechanisms of lung injury have not been fully elucidated. The pathogenesis of this neonatal condition is based on the rapid formation of the oxygen reactive species, which surpasses the detoxification capacity of anti-oxidative defense system. The high reactivity of free radical leads to damage to a variety of molecules and may induce respiratory cell death. There is evidence that the oxidative stress involved in the physiopathology of this disease, is particularly related to oxygen supplementation, mechanical ventilation, inflammation/infe…

0301 basic medicineNeonatal respiratory distress syndromeRespiratory distress syndromemedicine.medical_treatmentDiseaseLung injurymedicine.disease_causeBiochemistry03 medical and health sciencesSurface-Active Agents0302 clinical medicineFetusPregnancyPhysiology (medical)MedicineHumansRespiratory systemMechanical ventilationRespiratory Distress Syndrome NewbornRespiratory distressContinuous Positive Airway Pressurebusiness.industryInfant NewbornLung InjuryNewbornmedicine.diseaseNewborn; Oxidative stress; Prematurity; Respiratory distress syndrome; VentilationRespiration ArtificialVentilationOxygenDiabetes GestationalOxidative Stress030104 developmental biologyImmunologyBreathingOxidative streFemalePrematuritybusinessReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressInfant Premature
researchProduct

Critical re-evaluation of neuroglobin expression reveals conserved patterns among mammals.

2016

Neuroglobin (Ngb) is a respiratory protein that is almost exclusively expressed in the vertebrate nervous system. Despite many years of research, the exact function and even the expression sites of Ngb are still a matter of debate. However, to investigate hypotheses surrounding the potential roles of Ngb, a detailed knowledge of its major and minor expression sites is indispensable. We have therefore evaluated Ngb expression by extensive bioinformatic analysis using publicly available transcriptome data (RNA-Seq). During mammalian brain development, we observed low embryonic expression of Ngb mRNA and an increase after birth, arguing against a role of Ngb in fetal hypoxia tolerance. In adul…

0301 basic medicineNervous systemCerebellumHypothalamusHippocampusNeuroglobinNerve Tissue ProteinsBiologyHippocampusTranscriptome03 medical and health sciencesMiceCerebellummedicineAnimalsRNA MessengerCerebral CortexMammalsNeuronsMessenger RNAGeneral NeuroscienceMolecular biologyCell biologyGlobinsRespiratory protein030104 developmental biologymedicine.anatomical_structureCerebral cortexNeuroglobinNeuroscience
researchProduct

The Action of Di-(2-Ethylhexyl) Phthalate (DEHP) in Mouse Cerebral Cells Involves an Impairment in Aryl Hydrocarbon Receptor (AhR) Signaling

2018

Di-(2-ethylhexyl) phthalate (DEHP) is used as a plasticizer in various plastic compounds, such as polyvinyl chloride (PVC), and products including baby toys, packaging films and sheets, medical tubing, and blood storage bags. Epidemiological data suggest that phthalates increase the risk of the nervous system disorders; however, the impact of DEHP on the brain cells and the mechanisms of its action have not been clarified. The aim of the present study was to investigate the effects of DEHP on production of reactive oxygen species (ROS) and aryl hydrocarbon receptor (AhR), as well as Cyp1a1 and Cyp1b1 mRNA and protein expression in primary mouse cortical neurons and glial cells in the in vit…

0301 basic medicineNervous systemendocrine systemCYP1B1Gene ExpressionNeocortexToxicologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiethylhexyl PhthalateGliaCytochrome P-450 CYP1A1medicineAnimalsCyp1a1RNA MessengerCells Culturedchemistry.chemical_classificationNeuronsReactive oxygen speciesMessenger RNADose-Response Relationship DrugbiologyDEHPChemistryGeneral NeuroscienceAhRPhthalateROSrespiratory systemAryl hydrocarbon receptorIn vitroCell biology030104 developmental biologymedicine.anatomical_structureReceptors Aryl HydrocarbonCytochrome P-450 CYP1B1biology.proteinOriginal ArticleSignal transductionReactive Oxygen SpeciesNeuroglia030217 neurology & neurosurgerySignal TransductionNeurotoxicity Research
researchProduct

α2 isoform of Na+,K+-ATPase via Na+,Ca2+ exchanger modulates myelin basic protein synthesis in oligodendrocyte lineage cells in vitro

2018

Abstract Oligodendrocytes in the CNS myelinate neuronal axons, facilitating rapid propagation of action potentials. Myelin basic protein (MBP) is an essential component of myelin and its absence results in severe hypomyelination. In oligodendrocyte lineage cell (OLC) monocultures MBP synthesis starts at DIV4. Ouabain (10 nM), a Na+,K+-ATPase (NKA) blocker, stimulates MBP synthesis. As OLCs express the α2 isoform of NKA (α2-NKA) that has a high affinity for ouabain, we hypothesized that α2-NKA mediates this effect. Knockdown of α2-NKA with small interfering (si)RNA (α2-siRNA) significantly potentiated MBP synthesis at DIV4 and 5. This effect was completely blocked by KB-R7943 (1 μM), a Na+,C…

0301 basic medicineNeurofilamentbiologyPhysiologyChemistryCell Biologyrespiratory systemOligodendrocyteOuabainMyelin basic proteinCell biology03 medical and health sciencesMyelin030104 developmental biology0302 clinical medicinemedicine.anatomical_structureExtracellularmedicinebiology.proteinNa+/K+-ATPaseAxonMolecular Biology030217 neurology & neurosurgerymedicine.drugCell Calcium
researchProduct

Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis

2019

Abstract Neutrophil extracellular traps (NETs) are formed by polymorphonuclear neutrophils (PMN) and contribute to the innate host defense by binding and killing bacterial and fungal pathogens. Because NET formation depends on histone hypercitrullination by peptidylarginine deiminase 4 (PAD4), we used PAD4 gene deficient (Pad4-/-) mice in a mouse model of invasive pulmonary aspergillosis (IPA) to address the contribution of NETs to the innate host defense in vivo. After the induction (24 h) of IPA by i.t. infection with Aspergillus fumigatus conidia, Pad4-/- mice revealed lower fungal burden in the lungs, accompanied by less acute lung injury, TNFα and citH3 compared to wildtype controls. T…

0301 basic medicineNeutrophilsImmunologyMedizinApoptosisLung injuryExtracellular TrapsArticleAspergillus fumigatusMicrobiologyMice03 medical and health sciences0302 clinical medicineProtein-Arginine Deiminase Type 4In vivomedicineAnimalsHumansImmunology and Allergyskin and connective tissue diseasesLungInvasive Pulmonary AspergillosisMice KnockoutLungbiologyAspergillus fumigatusWild typeHematologyNeutrophil extracellular trapsbiology.organism_classificationmedicine.diseaseImmunity Innaterespiratory tract diseasesMice Inbred C57BLDisease Models AnimalPneumonia030104 developmental biologymedicine.anatomical_structureCitrullinationTumor necrosis factor alpha030215 immunologyImmunobiology
researchProduct

Meta-analysis of exome array data identifies six novel genetic loci for lung function

2018

Background: Over 90 regions of the genome have been associated with lung function to date, many of which have also been implicated in chronic obstructive pulmonary disease. Methods: We carried out meta-analyses of exome array data and three lung function measures: forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and the ratio of FEV1 to FVC (FEV1/FVC). These analyses by the SpiroMeta and CHARGE consortia included 60,749 individuals of European ancestry from 23 studies, and 7,721 individuals of African Ancestry from 5 studies in the discovery stage, with follow-up in up to 111,556 independent individuals. Results: We identified significant (P<2·8x10-7) associatio…

0301 basic medicineNonsynonymous substitutionVital capacityMedicine (miscellaneous)Genome-wide association studySingle-nucleotide polymorphismBiologyGenomeGeneral Biochemistry Genetics and Molecular Biologyhengityselimet03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineMedicine and Health SciencesmedicineCOPDGWASkeuhkotExome030304 developmental biologyGenetics0303 health sciencesCOPDexome arrayta1184Lung function respiratory exome array GWAS COPDBiology and Life Sciencesta3141lung functionArticlesGenomicsta3121respiratory systemrespiratorymedicine.diseaserespiratory tract diseases030104 developmental biology030220 oncology & carcinogenesisExpression quantitative trait lociResearch Article
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.

2020

The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The discovery of the EML4-ALK fusion gene in a limited subset of patients affected by NSCLC and the subsequent clinical development of crizotinib in 2011 has been an impressive milestone in lung cancer research. Unfortunately, acquired resistances regularly develop, hence disease progression occurs. Afterward, modern tyrosine kinase inhibitors (TKIs), such as ceritinib, alectinib, brigatinib, and lorlat…

0301 basic medicineOncologyAlectinibALK inhibitorsmedicine.medical_specialtybrigatinibBrigatinibmedicine.medical_treatmentPharmaceutical Sciencenon-small cell lung cancer (NSCLC)lcsh:Medicinelcsh:RS1-441ReviewALK inhibitorTargeted therapylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinelorlatinibInternal medicineDrug DiscoveryMedicineAnaplastic lymphoma kinaseceritinibalectinibensartinibcrizotinibCrizotinibCeritinibbusiness.industrylcsh:Rmedicine.diseaseLorlatinibrespiratory tract diseasesnon-small cell lung cancer (NSCLC)030104 developmental biologytyrosine kinase inhibitors (TKIs)030220 oncology & carcinogenesisMolecular Medicinebusinessmedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

2017

Abstract: Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinas…

0301 basic medicineOncologyAlectinibmedicine.medical_specialtyAfatinibReview03 medical and health scienceschemistry.chemical_compoundangiogenesis0302 clinical medicineInternal medicinemedicinenintedanibOsimertinibnon-small cell lung cancerclinical trialsCeritinibCrizotinibbusiness.industrytarget therapyangiogenesiclinical trialGeneral Medicinerespiratory tract diseases030104 developmental biologyDocetaxelchemistry030220 oncology & carcinogenesissecond-line treatmentMedicineangiogenesis; clinical trials; nintedanib; non-small cell lung cancer; second-line treatment; target therapyNintedanibErlotinibHuman medicinebusinessmedicine.drug
researchProduct